Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
42
FDMT Quote, Financials, Valuation and Earnings
Last price:
$10.70
Seasonality move
:
3.13%
Day range:
$10.67 - $11.50
52-week range:
$2.24 - $12.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4,761.31x
P/B ratio:
1.66x
Volume:
485.7K
Avg. volume:
956.7K
1-year change:
56.89%
Market cap:
$611.3M
Revenue:
$37K
EPS (TTM):
-$3.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FDMT
4D Molecular Therapeutics, Inc.
|
$403K | -$0.98 | 2971114% | -51.32% | $33.11 |
|
AURA
Aura Biosciences, Inc.
|
-- | -- | -- | -- | $19.40 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FDMT
4D Molecular Therapeutics, Inc.
|
$10.70 | $33.11 | $611.3M | -- | $0.00 | 0% | 4,761.31x |
|
AURA
Aura Biosciences, Inc.
|
$6.43 | $19.40 | $408.3M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
OGEN
Oragenics, Inc.
|
$0.88 | $2.00 | $727K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.23 | $7.00 | $7.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FDMT
4D Molecular Therapeutics, Inc.
|
5.69% | 4.681 | 5.48% | 8.22x |
|
AURA
Aura Biosciences, Inc.
|
10.18% | 1.769 | 4.56% | 8.60x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FDMT
4D Molecular Therapeutics, Inc.
|
-$1.9M | -$61.2M | -42.83% | -45.02% | -67983.33% | -$46.4M |
|
AURA
Aura Biosciences, Inc.
|
-$300K | -$27.9M | -60.63% | -67.74% | -- | -$20.2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
4D Molecular Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns FDMT or AURA?
Aura Biosciences, Inc. has a net margin of -63195.56% compared to 4D Molecular Therapeutics, Inc.'s net margin of --. 4D Molecular Therapeutics, Inc.'s return on equity of -45.02% beat Aura Biosciences, Inc.'s return on equity of -67.74%.
Company Gross Margin Earnings Per Share Invested Capital FDMT4D Molecular Therapeutics, Inc.-2125.56% -$1.01 $391.2M AURAAura Biosciences, Inc.-- -$0.40 $174.4M -
What do Analysts Say About FDMT or AURA?
4D Molecular Therapeutics, Inc. has a consensus price target of $33.11, signalling upside risk potential of 209.45%. On the other hand Aura Biosciences, Inc. has an analysts' consensus of $19.40 which suggests that it could grow by 201.71%. Given that 4D Molecular Therapeutics, Inc. has higher upside potential than Aura Biosciences, Inc., analysts believe 4D Molecular Therapeutics, Inc. is more attractive than Aura Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FDMT4D Molecular Therapeutics, Inc.7 2 0 AURAAura Biosciences, Inc.5 0 0 -
Is FDMT or AURA More Risky?
4D Molecular Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aura Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock FDMT or AURA?
4D Molecular Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aura Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 4D Molecular Therapeutics, Inc. pays -- of its earnings as a dividend. Aura Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FDMT or AURA?
4D Molecular Therapeutics, Inc. quarterly revenues are $90K, which are larger than Aura Biosciences, Inc. quarterly revenues of --. 4D Molecular Therapeutics, Inc.'s net income of -$56.9M is lower than Aura Biosciences, Inc.'s net income of -$26.1M. Notably, 4D Molecular Therapeutics, Inc.'s price-to-earnings ratio is -- while Aura Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 4D Molecular Therapeutics, Inc. is 4,761.31x versus -- for Aura Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FDMT4D Molecular Therapeutics, Inc.4,761.31x -- $90K -$56.9M AURAAura Biosciences, Inc.-- -- -- -$26.1M
-
Which has Higher Returns FDMT or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -63195.56% compared to 4D Molecular Therapeutics, Inc.'s net margin of -255.85%. 4D Molecular Therapeutics, Inc.'s return on equity of -45.02% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital FDMT4D Molecular Therapeutics, Inc.-2125.56% -$1.01 $391.2M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About FDMT or NBY?
4D Molecular Therapeutics, Inc. has a consensus price target of $33.11, signalling upside risk potential of 209.45%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that 4D Molecular Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe 4D Molecular Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FDMT4D Molecular Therapeutics, Inc.7 2 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is FDMT or NBY More Risky?
4D Molecular Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock FDMT or NBY?
4D Molecular Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. 4D Molecular Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FDMT or NBY?
4D Molecular Therapeutics, Inc. quarterly revenues are $90K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. 4D Molecular Therapeutics, Inc.'s net income of -$56.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, 4D Molecular Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 4D Molecular Therapeutics, Inc. is 4,761.31x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FDMT4D Molecular Therapeutics, Inc.4,761.31x -- $90K -$56.9M NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns FDMT or OGEN?
Oragenics, Inc. has a net margin of -63195.56% compared to 4D Molecular Therapeutics, Inc.'s net margin of --. 4D Molecular Therapeutics, Inc.'s return on equity of -45.02% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital FDMT4D Molecular Therapeutics, Inc.-2125.56% -$1.01 $391.2M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About FDMT or OGEN?
4D Molecular Therapeutics, Inc. has a consensus price target of $33.11, signalling upside risk potential of 209.45%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 126.37%. Given that 4D Molecular Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe 4D Molecular Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FDMT4D Molecular Therapeutics, Inc.7 2 0 OGENOragenics, Inc.1 0 0 -
Is FDMT or OGEN More Risky?
4D Molecular Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock FDMT or OGEN?
4D Molecular Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 4D Molecular Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FDMT or OGEN?
4D Molecular Therapeutics, Inc. quarterly revenues are $90K, which are larger than Oragenics, Inc. quarterly revenues of --. 4D Molecular Therapeutics, Inc.'s net income of -$56.9M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, 4D Molecular Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 4D Molecular Therapeutics, Inc. is 4,761.31x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FDMT4D Molecular Therapeutics, Inc.4,761.31x -- $90K -$56.9M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns FDMT or PTN?
Palatin Technologies has a net margin of -63195.56% compared to 4D Molecular Therapeutics, Inc.'s net margin of --. 4D Molecular Therapeutics, Inc.'s return on equity of -45.02% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FDMT4D Molecular Therapeutics, Inc.-2125.56% -$1.01 $391.2M PTNPalatin Technologies-- -- -- -
What do Analysts Say About FDMT or PTN?
4D Molecular Therapeutics, Inc. has a consensus price target of $33.11, signalling upside risk potential of 209.45%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than 4D Molecular Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than 4D Molecular Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FDMT4D Molecular Therapeutics, Inc.7 2 0 PTNPalatin Technologies0 0 0 -
Is FDMT or PTN More Risky?
4D Molecular Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock FDMT or PTN?
4D Molecular Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 4D Molecular Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FDMT or PTN?
4D Molecular Therapeutics, Inc. quarterly revenues are $90K, which are larger than Palatin Technologies quarterly revenues of --. 4D Molecular Therapeutics, Inc.'s net income of -$56.9M is higher than Palatin Technologies's net income of --. Notably, 4D Molecular Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 4D Molecular Therapeutics, Inc. is 4,761.31x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FDMT4D Molecular Therapeutics, Inc.4,761.31x -- $90K -$56.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns FDMT or TOVX?
Theriva Biologics, Inc. has a net margin of -63195.56% compared to 4D Molecular Therapeutics, Inc.'s net margin of --. 4D Molecular Therapeutics, Inc.'s return on equity of -45.02% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital FDMT4D Molecular Therapeutics, Inc.-2125.56% -$1.01 $391.2M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About FDMT or TOVX?
4D Molecular Therapeutics, Inc. has a consensus price target of $33.11, signalling upside risk potential of 209.45%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than 4D Molecular Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than 4D Molecular Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FDMT4D Molecular Therapeutics, Inc.7 2 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is FDMT or TOVX More Risky?
4D Molecular Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock FDMT or TOVX?
4D Molecular Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 4D Molecular Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FDMT or TOVX?
4D Molecular Therapeutics, Inc. quarterly revenues are $90K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. 4D Molecular Therapeutics, Inc.'s net income of -$56.9M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, 4D Molecular Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 4D Molecular Therapeutics, Inc. is 4,761.31x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FDMT4D Molecular Therapeutics, Inc.4,761.31x -- $90K -$56.9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
